CT-388
InvestigationalA dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.
RG-6912
6 human studies
- Preclinical
- 25%
- Human research
- 75%
Based on 8 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
CT-388 (INN enicepatide; also RO7795068) is a dual GLP-1/GIP receptor agonist that has completed Phase 1 and Phase 2 obesity trials, with Phase 3 trials beginning in 2026. Its mechanism is well-characterized based on the established biology of incretin hormones.
How It Works (Simplified)
CT-388 activates two hormone receptors simultaneously to reduce appetite and improve metabolism:
Signals fullness to the brain, slows stomach emptying, and enhances glucose-dependent insulin release from the pancreas.
Synergizes with GLP-1 for enhanced insulin secretion and directly improves fat cell function and lipid metabolism.
Dual receptor activation creates stronger satiety signals than single-receptor drugs, leading to reduced food intake.
Improves insulin sensitivity, reduces blood glucose levels, and may improve lipid profiles through multiple pathways.
Key Research: Chakravarthy MV et al. (2025) reported the first published CT-388 clinical data, including the Phase 1 trial (NCT04838405). PMID:41319798 Willard FS et al. (2020) established the mechanistic basis for cAMP-biased GLP-1/GIP dual agonism (in the related agent tirzepatide). PMID:32730231
Important Limitations
- CT-388 is investigational and not yet FDA approved
- Only Phase 1 efficacy data are peer-reviewed (4-week timepoint); the ~18.8% at 24 weeks is from an unpublished press release, and Phase 2/3 results are pending
- Specific receptor binding affinities not publicly disclosed
- Head-to-head comparisons with tirzepatide not yet available
- Long-term cardiovascular outcomes data not yet established
Based on the published Phase 1 trial: initial GI adaptation period with potential nausea and decreased appetite. Mean weight loss of 4.7-8.0% vs 0.5% placebo was observed by day 29, with improved glycemic parameters.
Continued weight loss expected as dose escalation proceeds and GI side effects typically diminish, based on incretin-class experience. CT-388 data beyond 4 weeks are not yet published.
A reported ~18.8% placebo-adjusted weight loss by 24 weeks comes from an unpublished Phase 1 extension (press release only, not peer-reviewed) and should be treated as preliminary. Peer-reviewed 24-week and 48-week data from the Phase 2 trials are pending.
Based on tirzepatide data, continued weight loss expected through 52-72 weeks. Maintenance of weight loss requires ongoing treatment. Long-term CT-388 data pending Phase 2/3 results.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
BPC-157
CautionBoth affect GI function. CT-388 slows gastric emptying significantly while BPC-157 has gastroprotective effects. Unclear if effects interact; monitor GI symptoms if combined.
Tirzepatide
AvoidBoth are dual GLP-1/GIP receptor agonists with overlapping mechanisms. Combining would duplicate effects and increase risk of severe GI adverse events. No clinical rationale for combination.
Semaglutide
AvoidCT-388 already activates GLP-1 receptors. Adding a GLP-1-only agonist would provide no additional benefit while increasing adverse event risk.
Survodutide
AvoidOverlapping GLP-1 receptor activation. Combining dual/triple agonists has no clinical rationale and would compound GI side effects.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare CT-388
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium · NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191
AOD-9604 is a modified human-growth-hormone fragment investigated for obesity and fat metabolism. Its obesity development program did not establish efficacy, and current regulatory sources identify major safety and quality gaps for unapproved or compounded products.
Cagrilintide
AM833 · NN9838
Investigational long-acting amylin analogue. REDEFINE 1 included a Phase 3 cagrilintide-only arm; Novo reports 11.8% mean weight loss versus 2.3% with placebo at 68 weeks using an on-treatment estimand. Dedicated RENEW Phase 3 monotherapy trials have started. Cagrilintide is also a CagriSema component.
CagriSema
Cagrilintide-Semaglutide · NNC0174-0833
Investigational fixed-dose cagrilintide plus semaglutide combination. Novo filed a US obesity NDA in December 2025. Its sponsor-reported REDEFINE 4 head-to-head trial missed non-inferiority versus tirzepatide; September 2026 REIMAGINE 5 and REDEFINE 9 toplines address different populations and doses. A filing and positive toplines are not FDA approval.
Ecnoglutide
XW003 · Sciwind GLP-1
A long-acting GLP-1 receptor agonist developed by Sciwind Biosciences. A Phase 3 obesity trial showed 13.2% weight loss at 40 weeks with once-weekly dosing. Primarily targeting China and Asian markets with potential for global expansion.
Compared With
16 comparisonsConditions Studied
3 entries- CT-388 for Obesity The published CT-388 Phase 1 trial (NCT04838405) showed mean weight loss of 4.7-8.0% vs 0.5% placebo at 4 weeks. A widely reported…
- CT-388 for Type 2 Diabetes The GLP-1/GIP dual agonist mechanism has proven effective for glycemic control with tirzepatide. CT-388 is expected to have simila…
- CT-388 for Metabolic Syndrome Dual incretin agonists like CT-388 address multiple components of metabolic syndrome including obesity, insulin resistance, and dy…